Market Cap
CHF27.8b
Last Updated
2020/08/12 20:36 UTC
Data Sources
Company Financials +
Executive Summary
Alcon, Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients.
Rewards
Risk Analysis
No risks detected for ALC from our risk checks.
Snowflake Analysis
Adequate balance sheet with reasonable growth potential.
Similar Companies
Share Price & News
How has Alcon's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALC has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
2.7%
ALC
2.6%
CH Medical Equipment
1.8%
CH Market
1 Year Return
-0.09%
ALC
2.9%
CH Medical Equipment
5.8%
CH Market
Return vs Industry: ALC underperformed the Swiss Medical Equipment industry which returned 0.9% over the past year.
Return vs Market: ALC underperformed the Swiss Market which returned 3% over the past year.
Shareholder returns
| ALC | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.7% | 2.6% | 1.8% |
| 30 Day | 7.0% | 6.9% | -0.06% |
| 90 Day | 5.3% | 15.4% | 8.0% |
| 1 Year | -0.09%-0.09% | 3.7%2.9% | 9.4%5.8% |
| 3 Year | n/a | 43.6%36.2% | 21.0%8.4% |
| 5 Year | n/a | 110.4%94.4% | 30.2%9.7% |
Price Volatility Vs. Market
How volatile is Alcon's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall St
Could The Alcon Inc. (VTX:ALC) Ownership Structure Tell Us Something Useful?1 day ago | Simply Wall St
Here's What Alcon Inc.'s (VTX:ALC) Shareholder Ownership Structure Looks Like1 month ago | Simply Wall St
Is Alcon (VTX:ALC) Using Capital Effectively?Valuation
Is Alcon undervalued compared to its fair value and its price relative to the market?
9.9%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ALC (CHF57.26) is trading below our estimate of fair value (CHF63.52)
Significantly Below Fair Value: ALC is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: ALC is unprofitable, so we can't compare its PE Ratio to the CH Medical Equipment industry average.
PE vs Market: ALC is unprofitable, so we can't compare its PE Ratio to the Swiss market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALC is good value based on its PB Ratio (1.6x) compared to the CH Medical Equipment industry average (5.1x).
Next Steps
Future Growth
How is Alcon forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?
72.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.2%).
Earnings vs Market: ALC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ALC's is expected to become profitable in the next 3 years.
Revenue vs Market: ALC's revenue (8% per year) is forecast to grow faster than the Swiss market (3.7% per year).
High Growth Revenue: ALC's revenue (8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALC's Return on Equity is forecast to be low in 3 years time (3.3%).
Next Steps
Past Performance
How has Alcon performed over the past 5 years?
-55.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALC is currently unprofitable.
Growing Profit Margin: ALC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALC is unprofitable, and losses have increased over the past 5 years at a rate of 55.8% per year.
Accelerating Growth: Unable to compare ALC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-41.5%).
Return on Equity
High ROE: ALC has a negative Return on Equity (-3.15%), as it is currently unprofitable.
Next Steps
Financial Health
How is Alcon's financial position?
Financial Position Analysis
Short Term Liabilities: ALC's short term assets ($4.1B) exceed its short term liabilities ($2.1B).
Long Term Liabilities: ALC's short term assets ($4.1B) do not cover its long term liabilities ($5.9B).
Debt to Equity History and Analysis
Debt Level: ALC's debt to equity ratio (18%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if ALC's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable ALC has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: ALC is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 40.8% per year.
Next Steps
Dividend
What is Alcon current dividend yield, its reliability and sustainability?
0.23%
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: ALC is not paying a notable dividend for the Swiss market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALC's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.1yrs
Average management tenure
CEO
David Endicott (55 yo)
2.08yrs
Tenure
US$6,820,492
Compensation
Mr. David J. Endicott had been the Chief Executive Officer of Alcon, Inc. since July 1, 2018. Mr. Endicott has been the President of Hospira Medical Devices at Hospira Inc. since March 10, 2014. Mr. Endico ...
CEO Compensation Analysis
Compensation vs Market: David's total compensation ($USD6.82M) is about average for companies of similar size in the Swiss market ($USD6.48M).
Compensation vs Earnings: Insufficient data to compare David's compensation with company performance.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.08yrs | US$6.82m | 0.0052% $ 1.5m | |
| Senior VP & CFO | 1.33yrs | no data | no data | |
| Chief Accounting Officer | no data | no data | no data | |
| Senior VP & Chief Information Officer | no data | no data | no data | |
| Senior VP and Head of Global Investor Relations & Communications | no data | no data | no data | |
| Senior VP | no data | no data | no data | |
| Senior VP and Head Corporate Development | no data | no data | no data | |
| Senior VP & Chief HR Officer | 0.083yr | no data | no data | |
| President of North America | 5yrs | no data | 0.00086% $ 238.8k | |
| Senior VP and Head of Global Manufacturing & Technical Operations | no data | US$2.03m | no data | |
| President of Global Business & Innovation | 5.58yrs | no data | 0.0013% $ 366.5k | |
| Senior VP and Head of Global R&D | no data | no data | no data |
2.1yrs
Average Tenure
53yo
Average Age
Experienced Management: ALC's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 2.08yrs | US$6.82m | 0.0052% $ 1.5m | |
| Chairman | no data | US$597.37k | 0.0027% $ 755.3k | |
| Independent Director | 1.58yrs | US$153.43k | 0.00037% $ 102.7k | |
| Independent Director | 1.58yrs | US$192.42k | 0.00019% $ 52.8k | |
| Independent Director | 1.58yrs | US$152.80k | 0.00016% $ 44.4k | |
| Independent Director | 1.58yrs | US$132.68k | 0.0018% $ 508.2k | |
| Independent Director | 1.58yrs | US$145.88k | 0.00035% $ 97.2k | |
| Independent Director | 1.58yrs | US$157.20k | 0.00025% $ 69.4k | |
| Independent Director | 1.58yrs | US$150.28k | 0.00035% $ 97.2k | |
| Director | 1.58yrs | US$240.79k | 0.00025% $ 69.4k |
1.6yrs
Average Tenure
58.5yo
Average Age
Experienced Board: ALC's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Alcon Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Alcon Inc.
- Ticker: ALC
- Exchange: SWX
- Founded: 1945
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: CHF27.768b
- Shares outstanding: 484.95m
- Website: https://www.alcon.com
Number of Employees
Location
- Alcon Inc.
- Chemin de Blandonnet 8
- 1214 Vernier
- Geneva
- Geneva
- Switzerland
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| 2U3 | BST (Boerse-Stuttgart) | Yes | Common Shares | DE | EUR | Apr 2019 |
| ALC N | BMV (Bolsa Mexicana de Valores) | Yes | Common Shares | MX | MXN | Apr 2019 |
| 2U3 | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Apr 2019 |
| ALC | SWX (SIX Swiss Exchange) | Yes | Common Shares | CH | CHF | Apr 2019 |
| ALC | NYSE (New York Stock Exchange) | Yes | Common Shares | US | USD | Apr 2019 |
| 0A0D | LSE (London Stock Exchange) | Yes | Common Shares | GB | USD | Apr 2019 |
Biography
Alcon, Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients. It operates through two segments, Surgical and ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/08/12 20:36 |
| End of Day Share Price | 2020/08/12 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.